Nature Biotechnology Contents: Volume 30 pp 567 - 724

TABLE OF CONTENTS July 2012 Volume 30, Issue 7 In This Issue Focus Editorial News Bioentrepreneur Opinion and Comment Features News and Views Research Highlights Computational Biology Research Careers and Recruitment Subscribe   Facebook   RSS   Recommend to library   Twitter   Advertisement Natural products continue to underpin the developments of new medicines and agrochemicals. DBIII is the latest in the series of the Royal Society of Chemistry's successful Directing Biosynthesis series of conferences, featuring contributions from the most active groups in Europe, USA and Japan working in this rapidly developing area. Submit and register now   Advertisement BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities   Advertisement Nature Methods Focus on Bioimage Informatics The need to extract quantitative data from increasingly large and complex microscopy datasets requires sophisticated image acquisition and analysis methods and software. This focus issue discusses these tools and the challenges and opportunities in the field. Click here to access the focus.   In This Issue Top In this issue   ppvii - viii doi:10.1038/nbt.2309 Focus Top Cancer Technologies Increased understanding of the molecular defects associated with malignancies is opening up new opportunities in diagnosis and therapy. This focus issue of Nature Biotechnology highlights a selection of new technologies that promise to facilitate the development of more effective cancer treatments. Table of Contents Editorial Top Recasting cancer trials   p567 doi:10.1038/nbt.2315 Wanted: faster, more effective ways of testing experimental cancer drugs for both single-agent and combination treatments. News Top Swiss hope for phoenix from Merck Serono's ashes   pp569 - 570 Nuala Moran doi:10.1038/nbt0712-569 FDA approves pertuzumab   p570 Cormac Sheridan doi:10.1038/nbt0712-570 Canada approves stem cell product   p571 David Cyranoski doi:10.1038/nbt0712-571b NCATS launches drug repurposing program   pp571 - 572 Malorye Allison doi:10.1038/nbt0712-571a California's CIRM courts industry   p572 Jennifer Rohn doi:10.1038/nbt0712-572 Coalition aims to accelerate translation of cell therapies   pp573 - 574 Gunjan Sinha doi:10.1038/nbt0712-573 Jazz beefs up with EUSA biologic   p574 Sabine Louet doi:10.1038/nbt0712-574a UK's life sciences pitch   p574 Barbara Nasto doi:10.1038/nbt0712-574b First FDA-approved beta-amyloid diagnostic hits the market   p575 Ken Garber doi:10.1038/nbt0712-575 Obama administration report underlines support for biotech   p576 Emily Waltz doi:10.1038/nbt0712-576a Around the world in a month   p576 doi:10.1038/nbt0712-576b Debate over details of US biosimilar pathway continues to rage   p577 Jeffrey L Fox doi:10.1038/nbt0712-577 News Features Beyond counting tumor cells   pp578 - 580 Jim Kling doi:10.1038/nbt.2295 Since the discovery of circulating tumor cells in 1869, researchers have been able to do little else beyond count them. This is about to change, as advanced technologies for harvesting and analyzing rare cells from blood are opening the window for characterization. Jim Kling reports. Reading cancer's blueprint   pp581 - 584 Michael Eisenstein doi:10.1038/nbt.2292 Coinciding with last month's annual meeting of the American Society of Clinical Oncology, at least one business launched with a plan to use genetic information from patient tumors to help guide treatment. Michael Eisenstein investigates. Bioentrepreneur Top From academic solos to industrial symphonies   pp585 - 587 Gwen Acton, Alicia Gomez-Yafal and Emily Walsh doi:10.1038/nbt.2245 Opinion and Comment Top Correspondence Gene therapy matures in the clinic   pp588 - 593 Leonard W Seymour and Adrian J Thrasher doi:10.1038/nbt.2290 TAL effector RVD specificities and efficiencies   pp593 - 595 Jana Streubel, Christina Blucher, Angelika Landgraf and Jens Boch doi:10.1038/nbt.2304 Commentary Incorporating biomarkers into clinical trial designs: points to consider   pp596 - 599 Edward Bradley doi:10.1038/nbt.2296 In an environment where the regulatory and reimbursement authorities continue to raise the bar for new oncology therapies, how are sponsors adapting clinical trial designs? The Multiple Myeloma Research Foundation's evolving focus on drug R&D   pp600 - 603 Kathy Giusti doi:10.1038/nbt.2297 The Multiple Myeloma Research Foundation (MMRF) has developed innovative, collaborative business models to reshape the R&D enterprise with the single-minded focus of accelerating the development of new treatments for patients to extend their lives and lead to a cure. Features Top The challenges posed by cancer heterogeneity   pp604 - 610 Sangeeta Bhatia, John V Frangioni, Robert M Hoffman, A John Iafrate and Kornelia Polyak doi:10.1038/nbt.2294 A panel of five experts discuss the implications of cancer heterogeneity for diagnostics and therapy. T-cell therapy at the threshold   pp611 - 614 Carl June, Steven A Rosenberg, Michel Sadelain and Jeffrey S Weber doi:10.1038/nbt.2305 Despite impressive clinical activity in B-cell lymphoma and melanoma, questions remain about the immunobiology of adoptive T-cell therapies. Patents Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope   pp615 - 618 Colin G Sandercock and Ulrich Storz doi:10.1038/nbt.2291 It may be possible to patent both antibodies to new targets and later-developed antibodies to known targets. Recent patent applications in cancer biomarkers   p619 doi:10.1038/nbt.2308 News and Views Top ABSOLUTE cancer genomics   pp620 - 621 Peter Van Loo and Peter J Campbell doi:10.1038/nbt.2293 Calculating absolute copy numbers in cancer genome sequences identifies disease-associated genes and provides insights into tumor evolution and heterogeneity. New lysine methyltransferase drug targets in cancer   pp622 - 623 Tobias Wagner and Manfred Jung doi:10.1038/nbt.2300 Recent preclinical studies suggest that inhibitors of histone methyltransferases represent promising drug candidates for cancer therapy. The sweet allure of XNA   pp624 - 625 Fintan R Steele and Larry Gold doi:10.1038/nbt.2298 Oligonucleotides with unnatural sugar backbones that can be replicated in vitro may open up new avenues for synthetic biology and beyond. Biotchnology JOBS of the week The Arturo Falaschi ICGEB Flexible Fellowships International Centre for Genetic Engineering and Biotechnology Faculty Members Regional Centre for Biotechnology / NCR Open Positions in Biotechnology and Health Samsung Advanced Institute of Technology CISIA (Integrated kwnoledges for the sustainability and the innovation of Made in Italy in agri-food) CNR - Istituto di Biologia e Biotecnologia Agraria Scientist / Senior Scientist Advanced Cell Technology, Inc More Science jobs from Biotchnology EVENT IBS 2012(International Biotechnology Symposium & Exhibition) September 16-21, 2012 Daegu, Korea More science events from Research Highlights Top Plant genomics roundup | CNVs from exome sequencing | Keeping gut bugs from causing harm | siRNAs on the edge | Mending hearts in situ Computational Biology Top Commentary Compressive genomics   pp627 - 630 Po-Ru Loh, Michael Baym and Bonnie Berger doi:10.1038/nbt.2241 Algorithms that compute directly on compressed genomic data allow analyses to keep pace with data generation. Research Top Perspective The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma   pp631 - 637 Peter D Senter and Eric L Sievers doi:10.1038/nbt.2289 Reviews From single cells to deep phenotypes in cancer   pp639 - 647 Sean C Bendall and Garry P Nolan doi:10.1038/nbt.2283 Modeling and predicting clinical efficacy for drugs targeting the tumor milieu   pp648 - 657 Mallika Singh and Napoleone Ferrara doi:10.1038/nbt.2286 Oncolytic virotherapy   pp658 - 670 Stephen J Russell, Kah-Whye Peng and John C Bell doi:10.1038/nbt.2287 Therapeutic targets in cancer cell metabolism and autophagy   pp671 - 678 Heesun Cheong, Chao Lu, Tullia Lindsten and Craig B Thompson doi:10.1038/nbt.2285 Combinatorial drug therapy for cancer in the post-genomic era   pp679 - 692 Bissan Al-Lazikani, Udai Banerji and Paul Workman doi:10.1038/nbt.2284 Articles Hybrid error correction and de novo assembly of single-molecule sequencing reads   pp693 - 700 Sergey Koren, Michael C Schatz, Brian P Walenz, Jeffrey Martin, Jason T Howard, Ganeshkumar Ganapathy, Zhong Wang, David A Rasko, W Richard McCombie, Erich D Jarvis and Adam M Phillippy doi:10.1038/nbt.2280 Single-molecule sequencing technologies can produce multikilobase-long reads, which are more useful than short reads for assembling genomes and transcriptomes, but their error rates are too high. Koren et al. correct long reads from a PacBio instrument using high-fidelity, short reads from complementary technologies, facilitating assembly of previously intractable sequences. A hybrid approach for the automated finishing of bacterial genomes   pp701 - 707 Ali Bashir, Aaron A Klammer, William P Robins, Chen-Shan Chin, Dale Webster, Ellen Paxinos, David Hsu, Meredith Ashby, Susana Wang, Paul Peluso, Robert Sebra, Jon Sorenson, James Bullard, Jackie Yen, Marie Valdovino, Emilia Mollova, Khai Luong, Steven Lin, Brianna LaMay, Amruta Joshi, Lori Rowe, Michael Frace, Cheryl L Tarr, Maryann Turnsek, Brigid M Davis, Andrew Kasarskis, John J Mekalanos, Matthew K Waldor and Eric E Schadt doi:10.1038/nbt.2288 The multikilobase reads that can be produced by single-molecule sequencing technologies may span complex, repetitive genomic regions but have high error rates. Bashir et al. use these reads to organize contigs assembled from accurate, short-read data, facilitating the analysis of clinically important regions of an outbreak strain of cholera. Tandem fluorescent protein timers for in vivo analysis of protein dynamics   pp708 - 714 Anton Khmelinskii, Philipp J Keller, Anna Bartosik, Matthias Meurer, Joseph D Barry, Balca R Mardin, Andreas Kaufmann, Susanne Trautmann, Malte Wachsmuth, Gislene Pereira, Wolfgang Huber, Elmar Schiebel and Michael Knop doi:10.1038/nbt.2281 Khmelinskii et al. describe tandem fluorescent protein timers for measuring protein turnover and trafficking in living cells. Data from a single time point are used to determine protein stability, allowing the authors to screen for components of protein degradation pathways. Letter Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors   pp715 - 720 Stuart M Chambers, Yuchen Qi, Yvonne Mica, Gabsang Lee, Xin-Jun Zhang, Lei Niu, James Bilsland, Lishuang Cao, Edward Stevens, Paul Whiting, Song-Hai Shi and Lorenz Studer doi:10.1038/nbt.2249 Chambers et al. use a combination of small-molecule pathway inhibitors to rapidly differentiate human pluripotent stem cells into nociceptors, a type of sensory neuron. The conversion occurs about three-fold faster than during development, suggesting that pathway inhibition may offer a general approach for speeding up the generation of specific cell types in vitro. Careers and Recruitment Top Managing knowledge-intensive workers   pp721 - 723 Sebastiano Massaro doi:10.1038/nbt.2299 A manager's ability to provide knowledge workers with the personalized goals, motivation and tools they need to perform at their best will bring outstanding results. People People   p724 doi:10.1038/nbt.2306 Top Advertisement Scientific Reports publishes 457 open access papers in its first year Publishing technically sound research articles, Scientific Reports is Nature Publishing Group’s fastest growing journal. Given the speed and visibility offered, no wonder 93% of our authors said that they are “likely” or “very likely” to submit again. Keep your research moving. Submit to Scientific Reports   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.